T1	Participants 42 93	secondary hyperparathyroidism in stages 3 and 4 CKD
T2	Participants 512 554	patients with stages 3 and 4 CKD with SHPT
T3	Participants 220 302	secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD)
T4	Participants 1243 1325	Two hundred twenty patients participated (n = 107, paricalcitol; n = 113, placebo)
